Brussels, 24 June 2026 - EuropaBio welcomes CrystalsFirst as its newest member.

Founded in Hamburg, Germany, CrystalsFirst is a European drug discovery services company helping biotech and pharmaceutical partners de‑risk early‑stage discovery and advance novel therapeutics. The company integrates protein sciences, structure determination, and AI‑enabled molecular design, building on patented academic technologies.

CrystalsFirst aims to accelerate early drug discovery by translating cutting‑edge science into practical, high‑impact solutions. Its work across multiple therapeutic modalities supports a more efficient and competitive European biotech value chain.

In joining EuropaBio, CrystalsFirst seeks to contribute its hands‑on SME perspective to discussions on innovation, intellectual property, and Europe’s ability to translate scientific excellence into medicines.

Dr. Claire Skentelbery, Director General of EuropaBio, said: “Europe is really defined by the expertise that it brings into frontier science, and small companies are the backbone of this. CrystalsFirst is a perfect example of this, enabling innovators to grow competitively and add value quickly.”

Dr. Serghei Glinca, Founder & CEO at CrystalsFirst, said: "We are pleased to join EuropaBio and contribute to a strong, competitive European biotech ecosystem. At CrystalsFirst, our mission is to help partners de-risk early drug discovery by combining protein science, structural biology, and AI-enabled molecular design. We look forward to working with EuropaBio and its members to advance innovation and support the translation of European science into new medicines."